AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Oppenheimer Maintains Hold Rating on Cellectar Biosciences with $18.00 Average Price Target
ByAinvest
Friday, Aug 15, 2025 11:55 am ET1min read
Oppenheimer maintains a Hold rating for Cellectar Biosciences (CLRB) with a consensus Moderate Buy rating and average price target of $18.00. CLRB's market cap is $11.83M and has a P/E ratio of -0.22.
Cellectar Biosciences (CLRB), a biotechnology company, experienced a volatile trading day on Thursday, August 14, 2025, with its stock price fluctuating between $4.33 and $4.94. Despite no significant changes in the stock's price, the company's stock has fallen in six of the last ten trading days, resulting in an 8.68% decline over this period [1].The stock's movement indicates a potential buying opportunity, as it lies in the lower part of a strong rising trend in the short term. Analysts predict the stock could rise by 89.62% in the next three months, with a 90% probability of holding a price between $7.71 and $25.35 [1]. However, several negative signals have been issued, including sell signals from both short and long-term moving averages and a sell signal from the 3-month Moving Average Convergence Divergence (MACD) [1].
On the earnings front, Cellectar Biosciences is scheduled to announce Q2 2025 earnings results on Thursday, August 14, 2025, before the market opens. The consensus EPS estimate is -$3.70, with the company having beaten EPS estimates 0% of the time over the last year and revenue estimates 0% of the time over the same period [2]. The company's Q2 GAAP EPS of -$3.39 was a beat by $0.31, with the company reporting approximately $11.0 million in cash and cash equivalents as of June 30, 2025 [3].
Oppenheimer maintains a Hold rating for Cellectar Biosciences (CLRB) with a consensus Moderate Buy rating and an average price target of $18.00. The company's market cap is $11.83 million, and its P/E ratio is -0.22 [1].
References:
[1] https://stockinvest.us/stock/CLRB
[2] https://seekingalpha.com/news/4484856-cellectar-biosciences-q2-2025-earnings-preview
[3] https://seekingalpha.com/news/4485266-cellectar-biosciences-gaap-eps-of-3_39-beats-by-0_31
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet